Andreia Domnica Tatar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andreia Domnica Tatar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anda Baicus
Department of Microbiology, University of Medicine and Pharmacy, Carol Davila, 020021 Bucharest, Romania
2 shared publications - Lore-Dana Barcer
Clinical Laboratory, Emergency University Hospital, 050098 Bucharest, Romania
2 shared publications - Monica Dugăeşescu
Department of Microbiology, University of Medicine and Pharmacy, Carol Davila, 020021 Bucharest, Romania
2 shared publications - Valentina Daniela Sisu
Department of Microbiology, University of Medicine and Pharmacy, Carol Davila, 020021 Bucharest, Romania
2 shared publications - Catalin Cirstoiu
Department of Orthopedics, University of Medicine and Pharmacy, Carol Davila, 020021 Bucharest, Romania
1 shared publication - Elena Andreea Birlescu
Department of Microbiology, University of Medicine and Pharmacy, Carol Davila, 020021 Bucharest, Romania
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (11) , 845
Distribution and Antifungal Susceptibility Profiles of Candida Species Isolated from Patients at a Romanian Tertiary Care Hospital
This study aimed to evaluate the species distribution and antifungal susceptibility profiles in Candida spp. isolates over a 17-month period in a tertiary care hospital from Bucharest, Romania. A total of 108 isolates retrieved from inpatients and outpatients were identified by MALDI-TOF and tested for susceptibility against a YO10 nine-agent panel provided by SensiTitreTM. Among the selection criteria for isolates were the sample’s origin and laboratory procedures used for antifungal testing. The MICs were interpreted according to the current CLSI breakpoints (M27M44S) and current ECVs (M57S). From a total of 92 Candida isolates with defined susceptibility breakpoints, 77 isolates (83.69%) were susceptible to fluconazole, and additionally, 11 N. glabratus (11/12, one isolate resistant) were evaluated as susceptible-dose dependent (SDD). C. albicans was the most frequently isolated species, accounting for 56.48% of all strains (61/108 isolates). Susceptibility to fluconazole in this subgroup was 86.88% (53/61 isolates). Non-albicans species were represented by a total of 47 isolates (43 with established breakpoints). The fluconazole susceptibility rate was 83.87% (26/31 isolates), notably lower than C. albicans isolates, and it was calculated by excluding N. glabratus isolates. The finding of fluconazole-resistant C. parapsilosis sensu stricto in blood cultures (3 of 6 isolates) is clinically relevant. Although this is a small exploratory comparison, the result is in line with the Southern-European signal (ECMM Candida III). Echinocandins resistance rate (Anidulafungin, Micafungin, Caspofungin) was low (2.85%, 3/105 strains with defined susceptibility cut-offs) but not alternatively documented, with MICs ranging from 1 to 4 μg/mL in two C. albicans and one C. tropicalis isolate. This study underscores the importance of tracking local epidemiological data and antifungal susceptibility patterns given the diversity of patient groups in large medical units.
- 10 November 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (11) , 845
Open AccessDistribution and Antifungal Susceptibility Profiles of Candida Species Isolated from Patients at a Romanian Tertiary Care Hospital
This study aimed to evaluate the species distribution and antifungal susceptibility profiles in Candida spp. isolates over a 17-month period in a tertiary care hospital from Bucharest, Romania. A total of 108 isolates retrieved from inpatients and outpatients were identified by MALDI-TOF and tested for susceptibility against a YO10 nine-agent panel provided by SensiTitreTM. Among the selection criteria for isolates were the sample’s origin and laboratory procedures used for antifungal testing. The MICs were interpreted according to the current CLSI breakpoints (M27M44S) and current ECVs (M57S). From a total of 92 Candida isolates with defined susceptibility breakpoints, 77 isolates (83.69%) were susceptible to fluconazole, and additionally, 11 N. glabratus (11/12, one isolate resistant) were evaluated as susceptible-dose dependent (SDD). C. albicans was the most frequently isolated species, accounting for 56.48% of all strains (61/108 isolates). Susceptibility to fluconazole in this subgroup was 86.88% (53/61 isolates). Non-albicans species were represented by a total of 47 isolates (43 with established breakpoints). The fluconazole susceptibility rate was 83.87% (26/31 isolates), notably lower than C. albicans isolates, and it was calculated by excluding N. glabratus isolates. The finding of fluconazole-resistant C. parapsilosis sensu stricto in blood cultures (3 of 6 isolates) is clinically relevant. Although this is a small exploratory comparison, the result is in line with the Southern-European signal (ECMM Candida III). Echinocandins resistance rate (Anidulafungin, Micafungin, Caspofungin) was low (2.85%, 3/105 strains with defined susceptibility cut-offs) but not alternatively documented, with MICs ranging from 1 to 4 μg/mL in two C. albicans and one C. tropicalis isolate. This study underscores the importance of tracking local epidemiological data and antifungal susceptibility patterns given the diversity of patient groups in large medical units.
- Open Access
- 22 September 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 942
In Vitro Activity of Eravacycline, Aztreonam–Avibactam, and Cefiderocol Against Multidrug-Resistant Gram-Negative Clinical Isolates from a Romanian Tertiary Hospital
Background/Objectives: Carbapenem-resistant Gram-negative bacteria—especially NDM- and OXA-48-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii (CRAB)—have limited treatment options, and in vitro data from Eastern Europe on the reserve agents eravacycline, aztreonam–avibactam, and cefiderocol are scarce. We evaluated their in vitro activity against consecutive multidrug-resistant (MDR) Gram-negative isolates from a Romanian tertiary hospital, stratified by species and carbapenemase profile. Methods: Seventy-seven consecutive, non-duplicate MDR Gram-negative isolates were collected over a 12-week period (January–March 2026) at a single tertiary center and tested by gradient diffusion (Liofilchem MIC Test Strip). MTS was used as an exploratory screening method; reference broth microdilution (BMD) remains the standard for categorical susceptibility confirmation. MICs were interpreted using FDA and EUCAST v16.0 breakpoints. Carbapenemases were detected by immunochromatography (18 isolates), and carbapenemase-encoding genes were detected by Xpert Carba-R PCR (40 isolates of K. pneumoniae). Susceptibility is reported with Wilson 95% confidence intervals. Results: K. pneumoniae (n = 51) predominated; NDM+OXA-48 was the most common profile (43.1%), and NDM was present in 64.7%. Eravacycline inhibited 90.2% of K. pneumoniae, and aztreonam–avibactam inhibited 92.2%, both covering all NDM-only isolates (9/9). Cefiderocol inhibited 84.3% of K. pneumoniae overall, but only 6/9 (66.7%) of NDM-only producers versus 20/22 (90.9%) of NDM+OXA-48 co-producers, whereas eravacycline and aztreonam–avibactam remained active against all nine NDM-only isolates. Cefiderocol was the only agent active against P. aeruginosa (91.7%); aztreonam–avibactam showed uniformly high MICs against non-fermenters, and all 10 CRAB isolates had low eravacycline MICs (MIC50 0.064 µg/mL). Conclusions: The three agents were complementary: aztreonam–avibactam and eravacycline covered NDM-producing K. pneumoniae, whereas cefiderocol was less active in vitro; cefiderocol alone covered P. aeruginosa. Because MICs were generated by gradient diffusion, these exploratory benchmarks require confirmation by reference broth microdilution; gradient strips agree well with BMD for aztreonam–avibactam but show weaker, agent-dependent agreement for eravacycline and cefiderocol, so they are not yet a validated substitute across all three agents.
- 22 September 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 942
Open AccessIn Vitro Activity of Eravacycline, Aztreonam–Avibactam, and Cefiderocol Against Multidrug-Resistant Gram-Negative Clinical Isolates from a Romanian Tertiary Hospital
Background/Objectives: Carbapenem-resistant Gram-negative bacteria—especially NDM- and OXA-48-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii (CRAB)—have limited treatment options, and in vitro data from Eastern Europe on the reserve agents eravacycline, aztreonam–avibactam, and cefiderocol are scarce. We evaluated their in vitro activity against consecutive multidrug-resistant (MDR) Gram-negative isolates from a Romanian tertiary hospital, stratified by species and carbapenemase profile. Methods: Seventy-seven consecutive, non-duplicate MDR Gram-negative isolates were collected over a 12-week period (January–March 2026) at a single tertiary center and tested by gradient diffusion (Liofilchem MIC Test Strip). MTS was used as an exploratory screening method; reference broth microdilution (BMD) remains the standard for categorical susceptibility confirmation. MICs were interpreted using FDA and EUCAST v16.0 breakpoints. Carbapenemases were detected by immunochromatography (18 isolates), and carbapenemase-encoding genes were detected by Xpert Carba-R PCR (40 isolates of K. pneumoniae). Susceptibility is reported with Wilson 95% confidence intervals. Results: K. pneumoniae (n = 51) predominated; NDM+OXA-48 was the most common profile (43.1%), and NDM was present in 64.7%. Eravacycline inhibited 90.2% of K. pneumoniae, and aztreonam–avibactam inhibited 92.2%, both covering all NDM-only isolates (9/9). Cefiderocol inhibited 84.3% of K. pneumoniae overall, but only 6/9 (66.7%) of NDM-only producers versus 20/22 (90.9%) of NDM+OXA-48 co-producers, whereas eravacycline and aztreonam–avibactam remained active against all nine NDM-only isolates. Cefiderocol was the only agent active against P. aeruginosa (91.7%); aztreonam–avibactam showed uniformly high MICs against non-fermenters, and all 10 CRAB isolates had low eravacycline MICs (MIC50 0.064 µg/mL). Conclusions: The three agents were complementary: aztreonam–avibactam and eravacycline covered NDM-producing K. pneumoniae, whereas cefiderocol was less active in vitro; cefiderocol alone covered P. aeruginosa. Because MICs were generated by gradient diffusion, these exploratory benchmarks require confirmation by reference broth microdilution; gradient strips agree well with BMD for aztreonam–avibactam but show weaker, agent-dependent agreement for eravacycline and cefiderocol, so they are not yet a validated substitute across all three agents.